<DOC>
	<DOCNO>NCT00848692</DOCNO>
	<brief_summary>Based pilot patient observation , investigator anticipate chronic fatigue syndrome ( CFS ) patient may benefit B-cell depletion therapy . The hypothesis least subset CFS patient activate immune system involve B-lymphocytes , B-cell depletion may alleviate symptom .</brief_summary>
	<brief_title>Drug Intervention Chronic Fatigue Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>verify chronic fatigue syndrome ( CDCcriteria ) age &gt; 18 &lt; 60 year informed consent pregnancy lactation previous malignant disease except basal cell carcinoma skin cervical carcinoma situ previous longterm use immunosuppressive drug previous exposure rituximab endogenous depression multiallergy risk serious drug reaction reduce renal function ( creatinin &gt; 1.2 x UNL ) reduce liver function ( bilirubin transaminase &gt; 1.5 x UNL ) know HIV infection sign active viral infection pretreatment investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Chronic Fatigue Syndrome</keyword>
	<keyword>CFS</keyword>
	<keyword>Myalgic Encephalomyelitis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-lymphocyte depletion</keyword>
	<keyword>B-cell depletion</keyword>
</DOC>